Overview

HDCRT Plus Pembrolizumab in Advanced Malignancies

Status:
Completed

Trial end date:
2020-02-10

Target enrollment:

Participant gender:

Summary

This study is a pilot study to evaluate high-dose conformal radiation therapy (HDCRT) administered in combination with pembrolizumab in patients with solid tumors.

Phase:

Phase 1

Details

Lead Sponsor:

James Larner, MD

Treatments:

Pembrolizumab